FOXO4-DRI
Content:
15mg/vial x 1
Description
FOXO4-DRI (also known as Proxofim) is a 46-amino-acid synthetic peptide engineered using the D-retro-inverso (DRI) strategy, designed to selectively eliminate senescent cells—dysfunctional "aged" cells that accumulate over time and contribute to chronic inflammation, impaired tissue regeneration, and age-related decline. Developed by Peter de Keizer and colleagues at Erasmus University Medical Center, the peptide was first described in a landmark 2017 publication in the journal Cell.
FOXO4-DRI targets a specific protein-protein interaction between the FOXO4 transcription factor and the tumor suppressor p53, which is uniquely upregulated in senescent cells. By competitively disrupting this interaction, FOXO4-DRI releases p53 from nuclear sequestration, allowing it to translocate to mitochondria and trigger intrinsic apoptosis exclusively in senescent cells, while leaving healthy cells unaffected. This selectivity distinguishes FOXO4-DRI from broader senolytic agents like navitoclax, which can cause off-target effects including thrombocytopenia. The D-amino acid construction provides marked resistance to proteolytic degradation, extending its activity in the body.
Benefits
-
Selective Senescent Cell Clearance
Targets and eliminates dysfunctional aged cells while preserving healthy cells. -
Supports Healthy Aging
Reduces the burden of senescence-associated secretory phenotype (SASP) factors. -
Improves Vascular Function
Enhances endothelial function and vascular elasticity by reducing aging markers in the aorta. -
Supports Tissue Regeneration
Promotes healthier tissue remodeling and cellular communication. -
Enhances Cognitive Wellness
May help restore cerebral blood flow and blood-brain barrier integrity. -
Supports Muscle Recovery
Helps maintain physical resilience and recovery capacity. -
Reduces Chronic Inflammation
Lowers inflammatory burden associated with senescent cell accumulation. -
Promotes Long-Term Vitality
Supports overall physiological function associated with healthy aging.
Usage & Dosage Guidelines
Dosage should always be individualized according to treatment goals under professional supervision. Typical research protocols utilize an intermittent "hit-and-run" schedule with 3–6 doses per cycle, repeated 1–3 times per year.
Storage: Store lyophilized vials at 2–8°C; after reconstitution, refrigerate immediately and avoid freezing.
Cycle Support
Regular medical monitoring is recommended during extended longevity protocols. Maintain proper hydration and a nutrient-dense diet to support cellular health. Given the potent mechanism of action, professional supervision is essential to monitor response and adjust protocols as needed.
Stacking
FOXO4-DRI is commonly incorporated into comprehensive longevity and regenerative wellness protocols alongside mitochondrial-support peptides like MOTS-C, NAD+ therapies, regenerative peptides like BPC-157 and TB-500, or metabolic optimization compounds. Combination protocols should always be individualized according to treatment objectives and health status under professional supervision.
Contraindications
Do not use FOXO4-DRI if you are immunocompromised, have an active infection, are pregnant or breastfeeding, or are a child or adolescent. It is also contraindicated in individuals with active malignancy without professional oncology supervision.
Special Precautions
Critical Safety Warning: FOXO4-DRI is an experimental research peptide with no completed human clinical trials and no human safety data available as of 2026. Use should be limited to professionally supervised research settings only. Individuals with autoimmune disorders, chronic medical conditions, or undergoing immunosuppressive therapy should consult their physician before use.
Adverse Drug Reactions
Available adverse effect data is derived primarily from a single preclinical study in mice, including transient gastrointestinal disturbance and injection site reactions. Human safety profile has not been characterized. If severe or persistent effects occur, discontinue use and consult a healthcare professional.
Drug Interactions
Caution is advised when used with chemotherapy agents, immunosuppressant medications, or other senolytic agents such as dasatinib, quercetin, navitoclax, or fisetin, as additive or synergistic effects could cause excessive tissue damage. No formal drug interaction studies have been conducted.
Frequently Asked Questions (FAQs)
1. What is FOXO4-DRI used for?
FOXO4-DRI is an experimental senolytic peptide designed to selectively eliminate senescent (aged/dysfunctional) cells to support healthy aging, tissue regeneration, and overall vitality.
2. How does FOXO4-DRI work?
It disrupts the FOXO4-p53 interaction specifically in senescent cells, releasing p53 to trigger apoptosis (programmed cell death) while leaving healthy cells unaffected.
3. Is FOXO4-DRI FDA-approved?
No. FOXO4-DRI is not FDA- or EMA-approved for any indication and remains in the preclinical research stage with no completed human clinical trials.
4. Are there human safety data available?
No human safety data exists. The available information is derived from preclinical mouse studies only.
5. What is the recommended dosage?
No established human dose exists. Research community protocols range from 3–25 mg per injection on an intermittent schedule. Dosage should only be determined by a qualified healthcare professional.
6. What are the common side effects?
Reported effects in mouse studies include mild diarrhea and injection site reactions. Human side effects are unknown.
7. Who should not use FOXO4-DRI?
Do not use if you are immunocompromised, have an active infection, are pregnant or breastfeeding, or are a child or adolescent.
8. Can FOXO4-DRI be stacked with other products?
Theoretically, it may be combined with mitochondrial-support peptides, NAD+ therapies, or regenerative peptides, but combination protocols should only be determined by a qualified professional.
9. Is FOXO4-DRI safe for long-term use?
Long-term safety is completely unknown. No formal toxicology studies meeting regulatory standards exist.
10. Do I need post-cycle therapy (PCT) after using FOXO4-DRI?
FOXO4-DRI does not suppress natural hormones, so PCT is not required. Professional medical supervision is still essential.
Disclaimer
The information provided is for educational purposes only and is not intended as medical advice. FOXO4-DRI is an experimental research compound with no established human safety data and should only be used under the supervision of a qualified healthcare professional in an approved research setting. This product is not intended to diagnose, treat, cure, or prevent any disease. Product images are for illustration purposes only and may differ from the actual product. Packaging and labeling are subject to change without prior notice.
🛡️ FOXO4-DRI — Advanced Senolytic Peptide for Healthy Aging, Cellular Rejuvenation, Tissue Regeneration & Long-Term Vitality
